These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 25868800)
1. A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease. Paton-Hough J; Chantry AD; Lawson MA Bone; 2015 Aug; 77():57-68. PubMed ID: 25868800 [TBL] [Abstract][Full Text] [Related]
2. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease. Lawson MA; Paton-Hough JM; Evans HR; Walker RE; Harris W; Ratnabalan D; Snowden JA; Chantry AD PLoS One; 2015; 10(3):e0119546. PubMed ID: 25768011 [TBL] [Abstract][Full Text] [Related]
3. The use of animal models in multiple myeloma. Libouban H Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798 [TBL] [Abstract][Full Text] [Related]
4. Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system. Huang SY; Tien HF; Su FH; Hsu SM Am J Pathol; 2004 Feb; 164(2):747-56. PubMed ID: 14742278 [TBL] [Abstract][Full Text] [Related]
5. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364 [TBL] [Abstract][Full Text] [Related]
6. [Establishment of multiple myeloma mouse models expressing brain derived neurotrophic factor]. Wang YD; Hu Y; Zhang L; Huang J; Sun CY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):967-72. PubMed ID: 17956671 [TBL] [Abstract][Full Text] [Related]
7. Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies. Schueler J; Wider D; Klingner K; Siegers GM; May AM; Wäsch R; Fiebig HH; Engelhardt M PLoS One; 2013; 8(11):e79939. PubMed ID: 24223204 [TBL] [Abstract][Full Text] [Related]
8. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model]. Wang YD; Hu Y; Zhang L; Huang J; Sun CY Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169 [TBL] [Abstract][Full Text] [Related]
9. ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo. Lath DL; Buckle CH; Evans HR; Fisher M; Down JM; Lawson MA; Chantry AD PLoS One; 2018; 13(6):e0199517. PubMed ID: 29924867 [TBL] [Abstract][Full Text] [Related]
10. Reovirus as a viable therapeutic option for the treatment of multiple myeloma. Thirukkumaran CM; Shi ZQ; Luider J; Kopciuk K; Gao H; Bahlis N; Neri P; Pho M; Stewart D; Mansoor A; Morris DG Clin Cancer Res; 2012 Sep; 18(18):4962-72. PubMed ID: 22761466 [TBL] [Abstract][Full Text] [Related]
11. In vivo models of multiple myeloma (MM). Sanchez E; Chen H; Berenson JR Biochem Pharmacol; 2014 Jun; 89(3):313-20. PubMed ID: 24704250 [TBL] [Abstract][Full Text] [Related]
12. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. Carlo-Stella C; Guidetti A; Di Nicola M; Longoni P; Cleris L; Lavazza C; Milanesi M; Milani R; Carrabba M; Farina L; Formelli F; Gianni AM; Corradini P Exp Hematol; 2006 Jun; 34(6):721-7. PubMed ID: 16728276 [TBL] [Abstract][Full Text] [Related]
13. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma. Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048 [TBL] [Abstract][Full Text] [Related]
14. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Yata K; Yaccoby S Leukemia; 2004 Nov; 18(11):1891-7. PubMed ID: 15385929 [TBL] [Abstract][Full Text] [Related]
15. KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts. Miki H; Ozaki S; Nakamura S; Oda A; Amou H; Ikegame A; Watanabe K; Hiasa M; Cui Q; Harada T; Fujii S; Nakano A; Kagawa K; Takeuchi K; Yata K; Sakai A; Abe M; Matsumoto T Br J Haematol; 2011 Nov; 155(3):328-39. PubMed ID: 21902681 [TBL] [Abstract][Full Text] [Related]
16. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts. Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957 [TBL] [Abstract][Full Text] [Related]
18. The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines. Coleman EJ; Brooks KJ; Smallshaw JE; Vitetta ES J Immunother; 2006; 29(5):489-98. PubMed ID: 16971805 [TBL] [Abstract][Full Text] [Related]
19. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow. Yamashita K; Iwasaki T; Tsujimura T; Sugihara A; Yamada N; Ueda H; Okamura H; Futani H; Maruo S; Terada N Oncol Rep; 2002; 9(6):1237-44. PubMed ID: 12375027 [TBL] [Abstract][Full Text] [Related]
20. The antidepressant amitriptyline shows potent therapeutic activity against multiple myeloma. Zhang Z; Du X; Zhao C; Cao B; Zhao Y; Mao X Anticancer Drugs; 2013 Sep; 24(8):792-8. PubMed ID: 23708819 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]